Viridian Therapeutics, Inc.\DE vs Zentalis Pharmaceuticals
VRDN and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VRDN and ZNTL compare
Viridian Therapeutics, Inc.\DE is the larger company, worth 32 times as much as Zentalis Pharmaceuticals ($3.4B against $107M).
Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VRDN | ZNTL |
|---|---|---|
| Size and price | ||
| Market cap | $3.4B | $107M |
| Share price | $30.06 | $1.49 |
| Change, 1 year | 4.5% | 12.0% |
| Change, 5 years | 64.3% | −98.0% |
| Beta (5Y) | −0.13 | 5.80 |
| Employees | 252 | 106 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 47.9× | – |
| P/B | 5.1× | 0.7× (better) |
| FCF yield | −9.8% (better) | −120% |
| Fair value | $8.47 | – |
| Margin of safety | −255% | – |
| Growth | ||
| Revenue growth (TTM) | 23220% | – |
| Revenue growth, 5Y average | 132% | – |
| Profitability | ||
| Operating margin | −570% | – |
| Net margin | −544% | – |
| FCF margin | −471% | – |
| Return on equity | −65.7% (better) | −66.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −26.0× | – |
| Current ratio | 16.95 (better) | 4.82 |
| Altman Z-score | 2.65 (better) | −8.91 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −1.7% | – |
| Shareholder yield | −1.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 120% | 66.1% |
| Held by insiders | 21.8% | 58.0% |
| Insider net buying, 12 months | $19.6M (better) | $12.8M |
| Short interest, % of float | 19.2% | 16.7% |
Go deeper
- VRDN stock overview
- VRDN income statement
- VRDN valuation and score
- ZNTL stock overview
- ZNTL income statement
- ZNTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.